Ian Vela
About
Ian Vela is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Ian Vela has authored 56 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Ian Vela's work include Prostate Cancer Treatment and Research (27 papers), Prostate Cancer Diagnosis and Treatment (18 papers) and Cancer Cells and Metastasis (13 papers). Ian Vela is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Prostate Cancer Diagnosis and Treatment (18 papers) and Cancer Cells and Metastasis (13 papers). Ian Vela collaborates with scholars based in Australia, United Kingdom and United States. Ian Vela's co-authors include Marlon Perera, Matthew J. Roberts, Nathan Lawrentschuk, Michael S. Hofman, Daniel Christidis, Declan G. Murphy, Nathan Papa, Damien Bolton, Cristian Udovicich and Michael B. Williams and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
Ian Vela
52 papers receiving 1.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ian Vela Australia | 21 | 1.3k | 509 | 476 | 353 | 252 | 56 | 1.7k | ||
| Martin Bögemann Germany | 22 | 1.6k 1.3× | 1.2k 2.3× | 510 1.1× | 327 0.9× | 236 0.9× | 86 | 1.9k | ||
| Sebastian Rogenhofer Germany | 22 | 1.0k 0.8× | 556 1.1× | 267 0.6× | 381 1.1× | 808 3.2× | 40 | 2.0k | ||
| Wolfgang Loidl Austria | 23 | 1.5k 1.2× | 768 1.5× | 448 0.9× | 247 0.7× | 140 0.6× | 71 | 1.9k | ||
| Akmal Safwat Denmark | 22 | 925 0.7× | 282 0.6× | 676 1.4× | 163 0.5× | 222 0.9× | 82 | 1.6k | ||
| Paul C.M.S. Verhagen Netherlands | 19 | 1.6k 1.3× | 371 0.7× | 196 0.4× | 289 0.8× | 267 1.1× | 49 | 1.9k | ||
| Sze Ting Lee Australia | 20 | 428 0.3× | 633 1.2× | 335 0.7× | 235 0.7× | 128 0.5× | 69 | 1.2k | ||
| Mario Eisenberger United States | 14 | 981 0.8× | 366 0.7× | 398 0.8× | 247 0.7× | 234 0.9× | 32 | 1.5k | ||
| Vito Cucchiara Italy | 27 | 1.3k 1.0× | 267 0.5× | 248 0.5× | 238 0.7× | 268 1.1× | 69 | 1.9k | ||
| Pieter De Visschere Belgium | 19 | 1.3k 1.0× | 492 1.0× | 169 0.4× | 98 0.3× | 111 0.4× | 64 | 1.6k | ||
| Peter J. Effert Germany | 17 | 708 0.6× | 312 0.6× | 379 0.8× | 262 0.7× | 350 1.4× | 35 | 1.5k |
Countries citing papers authored by Ian Vela
Since
Specialization
Citations
This map shows the geographic impact of Ian Vela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Vela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Vela more than expected).
Fields of papers citing papers by Ian Vela
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ian Vela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Vela. The network helps show where Ian Vela may publish in the future.
Co-authorship network of co-authors of Ian Vela
This figure shows the co-authorship network connecting the top 25 collaborators of Ian Vela. A scholar is included among the top collaborators of Ian Vela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Vela. Ian Vela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Roberts, Matthew J., Natasha Roberts, Anita Pelecanos, et al.. (2025). A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. EJNMMI Research. 15(1). 92–92.
2.
Semchenko, Evgeny A., et al.. (2025). Could Neisseria gonorrhoeae have carcinogenic potential? A critical review of current evidence. Critical Reviews in Microbiology. 51(6). 954–965.
3.
Zhu, Joe Jiang, Natalie L. Lister, Shivakumar Keerthikumar, et al.. (2023). Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nature Communications. 14(1). 5346–5346.
4.
Thomas, Patrick B., Gail P. Risbridger, Renea A. Taylor, et al.. (2022). Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers. 14(3). 503–503.
5.
Kapeleris, Joanna, Juliana Müller Bark, Derek J. Richard, et al.. (2022). Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition. Journal of Cancer Research and Clinical Oncology. 148(12). 3501–3510.
6.
Kapeleris, Joanna, Majid Ebrahimi Warkiani, Arutha Kulasinghe, et al.. (2022). Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update. Frontiers in Oncology. 12. 859152–859152.
7.
Dhiantravan, Nattakorn, Louise Emmett, Anthony M. Joshua, et al.. (2021). UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol). British Journal of Urology. 128(3). 331–342.
8.
Risbridger, Gail P., Laura H. Porter, Joe Jiang Zhu, et al.. (2021). Preclinical Evidence of the Efficacy of Lewis Y Car T Cells in Patient-Derived Models of Prostate Cancer. Journal of the Endocrine Society. 5(Supplement_1). A1029–A1030.
9.
Futrega, Kathryn, et al.. (2021). Using the Microwell-mesh to culture microtissues in vitro and as a carrier to implant microtissues in vivo into mice. Scientific Reports. 11(1). 5118–5118.
10.
Kapeleris, Joanna, Arutha Kulasinghe, Majid Ebrahimi Warkiani, et al.. (2020). Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer. Translational Lung Cancer Research. 9(5). 1795–1809.
11.
Roberts, Matthew C., et al.. (2020). Open retropubic radical prostatectomy. Translational Andrology and Urology. 9(6). 3025–3035.
12.
Jacobi, Angela, Mitchell G. Lawrence, Gail P. Risbridger, et al.. (2020). Cancer-associated fibroblasts of the prostate promote a compliant and more invasive phenotype in benign prostate epithelial cells. Materials Today Bio. 8. 100073–100073.
13.
Roberts, Matthew J., Marlon Perera, Elizabeth D. Williams, et al.. (2020). The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial. Clinical & Experimental Metastasis. 37(4). 551–560.
14.
Perera, Marlon, Nathan Papa, Matthew J. Roberts, et al.. (2019). Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. European Urology. 77(4). 403–417.
15.
Wood, Simon, et al.. (2017). Imaging tumour thrombus of clear cell renal cell carcinoma: FDG PET or PSMA PET? Direct in vivo comparison of two technologies. Urology Case Reports. 16. 4–5.
16.
Rhee, Handoo, Paul Thomas, Benjamin Shepherd, et al.. (2016). Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer. Queensland's institutional digital repository (The University of Queensland).
17.
Teleni, Laisa, Raymond J. Chan, Alexandre Chan, et al.. (2015). Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocrine Related Cancer. 23(2). 101–112.
18.
Vela, Ian, Colm Morrissey, Xilin Zhang, et al.. (2013). PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer. Clinical & Experimental Metastasis. 31(2). 199–211.
19.
Vela, Ian, Eva Corey, R L Vessella, et al.. (2010). Prostate cancer metastasis, the noncanonical Wnt pathway, and the transcription factor PITX2.. Journal of Clinical Oncology. 28(15_suppl). 4647–4647.
20.
Vela, Ian, Laura S. Gregory, Edith M. Gardiner, Judith A. Clements, & David Nicol. (2006). Bone and prostate cancer cell interactions in metastatic prostate cancer. British Journal of Urology. 99(4). 735–742.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Martin Bögemann Breakdown of academic impact, for papers by Sebastian Rogenhofer Breakdown of academic impact, for papers by Wolfgang Loidl Breakdown of academic impact, for papers by Akmal Safwat Breakdown of academic impact, for papers by Paul C.M.S. Verhagen Breakdown of academic impact, for papers by Sze Ting Lee Breakdown of academic impact, for papers by Mario Eisenberger Breakdown of academic impact, for papers by Vito Cucchiara Breakdown of academic impact, for papers by Pieter De Visschere Breakdown of academic impact, for papers by Peter J. Effert